In vitro and clinical evaluation of platelet-rich plasma combined with angioplasty in diabetic foot treatment

作者：Chen Huang, H. Eugene Liu, Jia-Bin Liang, Wei Zhao, Yansheng Wang, Li-Fen Ruan, Wei-Zhao Zhuang, Yongsheng Li, Qian Wang, Yukuan Tang · 发表于：World Journal of Diabetes · 年份：2025 · DOI：10.4239/wjd.v16.i10.110631 · 被引用次数：3 · 研究领域：Periodontal Regeneration and Treatments、Wound Healing and Treatments、Diabetic Foot Ulcer Assessment and Management

BACKGROUND Diabetic foot ulcers (DFUs) affect approximately 18.6 million people worldwide every year. Patients with DFU often present with symptoms such as lower limb infections, ulcers, and deep tissue damage. Platelet-rich plasma (PRP) is a concentrated platelet product that can trigger the release of growth factors and cytokines, which stimulate tissue healing and regeneration and thus alleviates DFU. At present, no comprehensive study has been conducted to verify the effect of PRP in both in vitro and clinical settings for treating DFUs. AIM To perform the in vitro and clinical evaluation of PRP combined with endovascular angioplasty in treating diabetic foot. METHODS This study focused on both in vitro and clinical settings. In the in vitro study, human umbilical vein endothelial cells (HUVECs), human dermal fibroblasts (HSFs), and human immortalized keratinocytes (HaCaTs) were treated with PRP. Experiments involving proliferation, migration, tubule formation, and angiogenesis signaling pathways were conducted. In this clinical study, patients who visited the Affiliated Panyu Central Hospital of Guangzhou Medical University from 2020 to 2024 and met enrollment criteria were randomly assigned to 2 groups using prospective block randomization. In the control group, the DFU was treated with endovascular angioplasty and wound debridement. In the PRP + endovascular angioplasty group, PRP was evenly used on the surface of superficial ulcers, followed by endovascular angioplast...